ClinicalTrials.gg
CompletedNCT05720494Updated Oct 1, 2024

A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JZP441 in Healthy Participants

A Phase 1 interventional study of JZP441 and Placebo in Healthy Participants, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Treatments for narcolepsy and hypersomnolence disorders should have good oral bioavailability and brain penetration properties. JZP441 has demonstrated wake-promoting efficacy and anticataplectic activity in nonclinical studies and may represent a novel approach for these patients.

Read the detailed description

This Phase 1, double-blind, randomized, placebo-controlled, parallel group study is designed to characterize the safety, tolerability, and PK of multiple ascending doses of JZP441 for up to 4 weeks in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
  • JZP441
03

In context

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 18 to 50 years of age inclusive, at the time of signing the
  • Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac/blood pressure monitoring.

Exclusion criteria

Exclusion Criteria:

  • History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that, in the investigator opinion, may interfere with absorption, distribution, metabolism, or excretion of drugs
  • Presence of renal impairment or calculated \< 80 mL/min/1.73 m\^2.
  • Triplicate 12-lead demonstrating a mean > 450 msec for males and > 470 msec for females or any other ECG abnormality per investigator assessment prior to dose of study intervention
  • Presence or history of significant cardiovascular disease including (but not limited to): myocardial infarction, uncontrolled hypertension, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (at Screening or baseline consistent with protocol specifications), angina pectoris, clinically significant arrhythmias, clinically significant valvular heart disease, history of any revascularization procedures or second or third degree heart block with/without a pacemaker, heart failure, or family history of Torsades de Pointes
  • Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode; history of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months)
  • History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or clinically significant psychiatric disorders, including other psychotic disorders
  • History (within past 2 years at Screening) or presence of substance use disorder (including alcohol) or seeking treatment for alcohol or substance abuse related disorder
  • History of seizure disorder or a physical condition that would increase seizure risk
  • History of head trauma or concussions that are deemed clinically significant by the investigator
  • Have used tobacco products or products for smoking cessation within 90 days before screening, including nicotine-containing products, or history of significant use of tobacco (> 10 cigarettes or equivalent per day) within 1 year before Screening, or unwilling to refrain from nicotine-containing products for the duration of the study
  • Participants who are taking a concomitant medication or supplement that lowers seizure threshold (eg, kratom)
  • Participants who have recently (\< 2 weeks) discontinued a drug or supplement for which discontinuation would lower seizure threshold (eg, benzodiazepine medication)
  • Participation in a previous JZP441 clinical study
  • Positive alcohol test or urine drug screen (including cannabinoids and cotinine) at Screening or at any point throughout the duration of the study
  • Presence at Screening of antibody, surface antigen, antibody, or a clinical history of these infections
  • History of clinically significant acute or chronic insomnia within the last 5 years
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    JZP441

    Healthy participants who will be randomized to receive an oral dose of JZP441.

    Drug: JZP441

  • Placebo comparator
    Placebo

    Healthy participants who will be randomized to receive placebo.

    Drug: Placebo

Interventions

  • DrugJZP441

    Oral study drug administered for up to 4 weeks

  • DrugPlacebo

    Oral placebo administered for up to 4 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Time frame: Day 1 up until 38 days after last dose of study drug, up to approximately 2 months

  2. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  3. Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP441

    Time to maximum plasma concentration (Tmax), time of maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Tmax1), and time of maximum observed plasma concentration post second dose during the 24-hour dosing interval (Tmax2), and time of last quantifiable concentration (Tlast) will be assessed.

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  4. Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2) of JZP441

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  5. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP441

    Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC0-last), and area under the concentration-time curve from time zero extrapolated to infinity (AUC∞) will be assessed.

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  6. Pharmacokinetic Parameter Apparent Oral Clearance (CL/F) of JZP441

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  7. Pharmacokinetic Parameter Apparent Volume of Distribution (Vz/F) of JZP441

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  8. Pharmacokinetic Parameter Accumulation Ratio of JZP441

    Accumulation ratio (Cmax) and accumulation ratio (AUC) will be assessed.

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  9. Dose Proportionality of JZP441 for Maximum Concentration (Cmax)

    Dose proportionality of maximum concentration (Cmax), maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Cmax1), and maximum observed plasma concentration post second dose during the 24-hour dosing interval (Cmax2) will be assessed.

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

  10. Dose Proportionality of JZP441 for Area Under the Concentration-Time Curve (AUC)

    Dose proportionality of area under the concentration-time curve from 0 to 24 hours (AUC\[0-24\]) will be assessed.

    Time frame: Pre-dose and multiple post-dose timepoints, up to Day 28

07

Study locations

1 site
  • Clinical Site 1
    Salt Lake City, Utah 84124, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Sep 2023, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 9, 2023
StartActual
Jan 26, 2023
Primary completionActual
Sep 29, 2023
CompletionActual
Sep 29, 2023
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05720494
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Jan 26, 2023
Primary completion
Sep 29, 2023
Completion
Sep 29, 2023
Last update
Oct 1, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JZP441

Start the discussion